Arcellx Inc (ACLX)
53.68
+0.88
(+1.68%)
USD |
NASDAQ |
May 17, 16:00
53.68
0.00 (0.00%)
After-Hours: 18:01
Arcellx Shareholders Equity (Quarterly): 496.57M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 496.57M |
| December 31, 2023 | 485.38M |
| September 30, 2023 | 266.13M |
| June 30, 2023 | 293.67M |
| March 31, 2023 | 303.72M |
| December 31, 2022 | 204.95M |
| Date | Value |
|---|---|
| September 30, 2022 | 236.28M |
| June 30, 2022 | 315.96M |
| March 31, 2022 | 221.59M |
| December 31, 2021 | -121.52M |
| September 30, 2021 | -103.80M |
| December 31, 2020 | -63.72M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-121.52M
Minimum
Dec 2021
496.57M
Maximum
Mar 2024
211.27M
Average
251.21M
Median
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences Inc | 17.54B |
| Eli Lilly and Co | 12.81B |
| Viking Therapeutics Inc | 933.89M |
| Blueprint Medicines Corp | 310.69M |
| NovaBay Pharmaceuticals Inc | 0.16M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 779.70M |
| Total Liabilities (Quarterly) | 283.12M |
| Current Ratio | 5.456 |